Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

National Cancer Institute (NCI) · 2026
ClinicalTrials.gov · Datasets · License: Public Domain · 2026
Open Source ↗
immunotherapytargeted-therapy
extensive-stage small cell lung cancer, extrapulmonary neuroendocrine carcinoma, small cell carcinoma, tarlatamab, sacituzumab govitecan, bispecific t-cell engager, immunotherapy, antibody drug conjugate, targeted therapy, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 870227
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.